PY 265
Alternative Names: PY-265Latest Information Update: 24 May 2024
Price :
$50 *
At a glance
- Originator Centre for the Commercialization of Antibodies and Biologics
- Developer Pionyr Immunotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunostimulants; Macrophage stimulants; Myeloid-derived suppressor cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer